Tuberculosis (TB) is a bacterial infection mainly affecting the lungs. TB is a major health problem worldwide and the occurrence of extensively drug-resistant TB (XDR-TB) and multidrug-resistant TB (MDR-TB) offers considerable hurdles to effective treatment and disease management. The growth of treatment-resistant Mycobacterium TB strains has prompted the investigation of alternate therapeutic techniques, including the application of sustained drug delivery. Sustained-release drugs reduce the need for frequent dosing can extend the effects of linezolid by 8 to 12 hours, thus improving the patient’s adherence to the treatment. The objective of this study is to formulate oral sustained-release linezolid tablets employing blends of polymers like hydroxy propyl methyl cellulose (HPMC)- K100M, ethyl cellulose, xanthan gum, and chitosan to provide sustained drug release. Linezolid was made into a sustained-release tablet by employing the direct compression method using different drug-polymer ratios. Formulated tablets were compared with marketed formulations to assess the similarity factor. The formulation was assessed for drug-excipient interaction, solubility, flow properties, etc. The diameter, friability, thickness, hardness, weight variation, in-vitro drug release, and drug release kinetics of compressed tablets were examined. Drug release research proved that all polymers were able to sustain drug release. Formulation (F5) with HPMC (100mg) and ethyl cellulose (100mg) resulted in 49.89% drug release after 8 hours, making it the optimal formulation. According to the kinetic model of the drug release, the Higuchi model was selected, which indicates the diffusion of the drug from an insoluble matrix. The optimized formulation showed a similarity factor of 52% with the marketed formulation, suggesting similarity in drug release between these two formulations.
Read full abstract